Our results indicate that the PCA3 score is a valid tool for prostate cancer detection and its role in making better biopsy decisions.
This marker [helps] to discriminate patients who have to undergo biopsy from patients who only need be actively surveilled: Quantitative PCA3 score is correlated with the probability of a positive result at biopsy.
Posts Tagged ‘PCA3’
Posted in Genetic testing, Urine test, tagged cancer research, catheter, messenger genes, PCA3, positive biopsy, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer detection, prostate cancer screening, Quantitative PCA3 score, urine samples, Urine test, URO TODAY on July 24, 2010 | Leave a Comment »
Posted in PROSTATE CANCER, PROSTATE RESEARCH, Urine test, tagged cancer research, medical checkups, PCA3, predictive value of PCA3, prognostic test, prostablog, prostate, prostate blog, prostate cancer screening, Screening debate, Urination, urine sediments, Urine test, URO TODAY on October 1, 2009 | Leave a Comment »
URO TODAY: Hopes for a urine test to tell how serious prostate cancer might be remain just that, following a new study just reported. READ MORE>
The predictive value of PCA3 for prostate cancer aggressiveness features as reported in earlier studies cannot be confirmed in our study. Experimental differences (urine sediments v whole urine) and cohort may explain this.
The exact place of PCA3 as prognostic test for prostate cancer remains the subject of investigation.
Posted in Diagnosis, PROSTATE CANCER, PROSTATE RESEARCH, PSA tests, tagged appropriate patient populations, assay standardisation, cancer detection, cancer research, optimal cutoff values, PCA3, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer antigen 3, prostate cancer prediction, prostate treatment debate, prostate-specific antigen, PSA, PSA test, URO TODAY on June 24, 2009 | Leave a Comment »
JUNE 24: URO TODAY: Adding prostate cancer antigen 3 to serum PSA improves prostate cancer prediction. The use of PCA3 in a clinical setting may help to stratify patients according to their risk for biopsy and cancer detection, although a large-scale validation study will be needed to address assay standardisation, optimal cutoff values, and appropriate patient populations. READ MORE>